<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103153</url>
  </required_header>
  <id_info>
    <org_study_id>CYN13-PICO532-RG5</org_study_id>
    <nct_id>NCT02103153</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos</brief_title>
  <official_title>Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the PICOSURE Laser System for the treatment of&#xD;
      unwanted tattoos&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tattoo Clearance Percentage Using a Photographic Scale</measure>
    <time_frame>1-3 month follow up post each subject's last treatment, an average of 17.5 months</time_frame>
    <description>Clearance will be measured using a clearance aesthetic improvement scale. This scale ranges from 0% to 100%, where 0% is 0% tattoo cleared compared to the baseline tattoo, and 100% is 100% of tattoo cleared compared to the baseline tattoo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Satisfaction</measure>
    <time_frame>Baseline and 2 months post last treatment follow up (+/- 1 month)</time_frame>
    <description>Questionnaires were used to assess Investigator satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>Baseline and 2 months post last treatment follow up (+/- 1 month)</time_frame>
    <description>Questionnaires were used to assess Subject satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Unwanted Tattoos</condition>
  <arm_group>
    <arm_group_label>Picosure Laser System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picosure Laser System</intervention_name>
    <arm_group_label>Picosure Laser System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is a healthy non-smoking (must have quit 6 months prior) male or female between 18 and&#xD;
             65 years old.&#xD;
&#xD;
          2. Is willing to consent to participate in the study.&#xD;
&#xD;
          3. Is willing to comply with all requirements of the study including being photographed,&#xD;
             following post treatment care and attending all treatment and follow up visits&#xD;
&#xD;
          4. Has unwanted non-cosmetic tattoo containing red ink, that has not previously been&#xD;
             treated, and wishes to undergo laser treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is female and pregnant, has been pregnant within the last 3 months, is&#xD;
             currently breast feeding or planning a pregnancy during the study period.&#xD;
&#xD;
          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.&#xD;
&#xD;
          3. The subject has active or localized systemic infections.&#xD;
&#xD;
          4. The subject has a coagulation disorder or is currently using anti-coagulation&#xD;
             medication (including but not limited to heavy aspirin therapy {greater than 81 mg per&#xD;
             day}).&#xD;
&#xD;
          5. The subject has any condition which, in the investigator's opinion, would make it&#xD;
             unsafe for the subject to participate in this research study.&#xD;
&#xD;
          6. The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             3 months prior to entering this study.&#xD;
&#xD;
          7. The subject has used Accutane within 6 months prior to enrollment.&#xD;
&#xD;
          8. The subject has the need to be exposed to artificial tanning devices or excessive&#xD;
             sunlight during the trial.&#xD;
&#xD;
          9. The subject has had prior treatment with parenteral gold therapy (gold sodium&#xD;
             thiomalate).&#xD;
&#xD;
         10. The subject has a history of keloids.&#xD;
&#xD;
         11. The subject has evidence of compromised wound healing.&#xD;
&#xD;
         12. The subject has a history of basal cell carcinoma, squamous cell carcinoma or&#xD;
             melanoma.&#xD;
&#xD;
         13. The subject has a history of immunosuppression/immune deficiency disorders (including&#xD;
             HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune&#xD;
             disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2021</results_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Picosure Laser System</title>
          <description>Subjects will be treated with 1064nm, 532nm, or 755nm in combination or individually, depending on the color of the tattoo and the skin type of the subject. Since the purpose of the study is to test the overall clearance of the tattoo, breaking the results down by wavelengths is extraneous information. The primary purpose of the study is not to compare the wavelengths against each other, but rather, to examine the overall clearance created by the Picosure Laser System. Furthermore, each wavelength is designed to target a specific color, so a multi-colored tattoo will have a variety of wavelengths used (in combination and individually), all for the primary objective of indicating overall tattoo clearance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Picosure Laser System</title>
          <description>Picosure Laser System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Score</title>
          <description>The Fitzpatrick Skin Score is used to determine skin color. It is a numerical system that classifies skin into six types (Type I, Type II, Type III, Type IV, Type V and Type VI) based on the numerical score achieved (ranging from 0 to 36). The lower the score (and skin type number), the fairer the skin. The higher the score (and skin type number), the more deeply pigmented the skin is.&#xD;
The scale comes from this source:&#xD;
Gupta, Sharma. Skin typing: Fitzpatrick grading and others. Clinics in Dermatology. 2019;37(5):430-436. doi:10.1016/j.clindermatol.2019.07.010</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fitzpatrick Skin Score I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Score II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Score III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Score IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Score V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Score VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tattoo Clearance Percentage Using a Photographic Scale</title>
        <description>Clearance will be measured using a clearance aesthetic improvement scale. This scale ranges from 0% to 100%, where 0% is 0% tattoo cleared compared to the baseline tattoo, and 100% is 100% of tattoo cleared compared to the baseline tattoo.</description>
        <time_frame>1-3 month follow up post each subject's last treatment, an average of 17.5 months</time_frame>
        <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Picosure Laser System</title>
            <description>Picosure Laser System, using a combination of combination or individual frequencies of 532 nm, 755 nm, or 1064 nm.</description>
          </group>
        </group_list>
        <measure>
          <title>Tattoo Clearance Percentage Using a Photographic Scale</title>
          <description>Clearance will be measured using a clearance aesthetic improvement scale. This scale ranges from 0% to 100%, where 0% is 0% tattoo cleared compared to the baseline tattoo, and 100% is 100% of tattoo cleared compared to the baseline tattoo.</description>
          <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
          <units>percentage of clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>tattoos</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tattoos</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Satisfaction</title>
        <description>Questionnaires were used to assess Investigator satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
        <time_frame>Baseline and 2 months post last treatment follow up (+/- 1 month)</time_frame>
        <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Picosure Laser System</title>
            <description>Subjects will be treated with 1064nm, 532nm, or 755nm in combination or individually, depending on the color of the tattoo and the skin type of the subject. Each wavelength is designed to target a specific color, so a multi-colored tattoo will have a variety of wavelengths used (in combination and individually), all for the primary objective of indicating overall tattoo clearance.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Satisfaction</title>
          <description>Questionnaires were used to assess Investigator satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
          <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
          <units>tattoos</units>
          <param>Count of Units</param>
          <units_analyzed>tattoos</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tattoos</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Tattoo Results Investigator Was Extremely Dissatisfied With</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Tattoo Results Investigator Was Dissatisfied With</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Tattoo Results Investigator Was Satisfied With</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Tattoo Results Investigator Was Extremely Satisfied With</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction</title>
        <description>Questionnaires were used to assess Subject satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
        <time_frame>Baseline and 2 months post last treatment follow up (+/- 1 month)</time_frame>
        <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
        <group_list>
          <group group_id="O1">
            <title>Picosure Laser System</title>
            <description>Subjects will be treated with 1064nm, 532nm, or 755nm in combination or individually, depending on the color of the tattoo and the skin type of the subject. Each wavelength is designed to target a specific color, so a multi-colored tattoo will have a variety of wavelengths used (in combination and individually), all for the primary objective of indicating overall tattoo clearance.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction</title>
          <description>Questionnaires were used to assess Subject satisfaction at the post last treatment follow up visit with their cosmetic results when compared to baseline photos using a four point scale ranging from &quot;extremely satisfied&quot; (3) to &quot;extremely dissatisfied&quot; (0).</description>
          <population>12 subjects were lost to follow up, and 5 subjects withdrew consent.</population>
          <units>tattoos</units>
          <param>Count of Units</param>
          <units_analyzed>tattoos</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tattoos</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of Tattoo Subjects Were Extremely Dissatisfied With</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of Tattoo Subjects Were Dissatisfied With</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of Tattoo Subjects Were Satisfied With</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of Tattoo Subjects Were Extremely Satisfied With</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events occurring will be captured and followed throughout the patients' participation in the study, approximately 23 months.</time_frame>
      <desc>Adverse Events were monitored/assessed without regard to the specific Adverse Event Term.</desc>
      <group_list>
        <group group_id="E1">
          <title>Picosure Laser System- 532 nm Wavelength</title>
          <description>Picosure Laser System, using a frequency of 532 nm</description>
        </group>
        <group group_id="E2">
          <title>Picosure Laser System- 755 nm Wavelength</title>
          <description>Picosure Laser System, using a frequency of 755 nm</description>
        </group>
        <group group_id="E3">
          <title>Picosure Laser System- 1064 nm Wavelength</title>
          <description>Picosure Laser System, using a frequency of 1064 nm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pinpoint Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Crusting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Scabbing</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blistering</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamie Trimper</name_or_title>
      <organization>Cynosure</organization>
      <phone>800-886-2966</phone>
      <email>jamie.trimper@cynosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

